CDK4 and breast carcinoma: Key findings were functionally validated using CDK4/6 inhibition in luminal cells and via immunohistochemistry on triple-negative breast cancer (TNBC) tissue microarrays.<h4>Results</h4>ITGB4 exhibited significant RNA-protein discordance across breast cancer subtypes.